Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 549

    1.

    Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.

    Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ; Fabry Disease Clinical Trial Study Group.

    Ann Intern Med. 2007 Jan 16;146(2):77-86. Epub 2006 Dec 18.PMID: 17179052 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

    Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N.

    J Am Soc Nephrol. 2007 May;18(5):1547-57. Epub 2007 Apr 4.PMID: 17409312 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Fabry disease: overall effects of agalsidase alfa treatment.

    Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A.

    Eur J Clin Invest. 2004 Dec;34(12):838-44.PMID: 15606727 [PubMed - indexed for MEDLINE]Related articles

    4.

    Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.

    Tahir H, Jackson LL, Warnock DG.

    J Am Soc Nephrol. 2007 Sep;18(9):2609-17. Epub 2007 Jul 26.PMID: 17656478 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme.

    Bodensteiner D, Scott CR, Sims KB, Shepherd GM, Cintron RD, Germain DP.

    Genet Med. 2008 May;10(5):353-8.PMID: 18496035 [PubMed - indexed for MEDLINE]Related articles

    6.

    Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.

    Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, Germain DP.

    J Pediatr. 2008 Apr;152(4):563-70, 570.e1. Epub 2007 Dec 3.PMID: 18346516 [PubMed - indexed for MEDLINE]Related articles

    7.

    Agalsidase alfa and kidney dysfunction in Fabry disease.

    West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R.

    J Am Soc Nephrol. 2009 May;20(5):1132-9. Epub 2009 Apr 8.PMID: 19357250 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.

    Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB.

    Heart. 2008 Feb;94(2):153-8. Epub 2007 May 4.PMID: 17483124 [PubMed - indexed for MEDLINE]Related articles

    9.

    Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.

    Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO.

    Nephrol Dial Transplant. 2006 Feb;21(2):345-54. Epub 2005 Oct 4.PMID: 16204287 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

    Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R.

    Pediatrics. 2006 Sep;118(3):924-32.PMID: 16950982 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Spotlight on agalsidase beta in Fabry disease.

    Keating GM, Simpson D.

    BioDrugs. 2007;21(4):269-71. Review.PMID: 17628124 [PubMed - indexed for MEDLINE]Related articles

    12.

    [Development of an orphan drug to treat a genetic disease: the paradigm of agalsidase beta]

    Germain DP, Benistan K.

    Presse Med. 2007 Mar;36 Spec No 1:1S69-75. Review. French. PMID: 17546772 [PubMed - indexed for MEDLINE]Related articles

    13.

    Agalsidase Beta: a review of its use in the management of Fabry disease.

    Keating GM, Simpson D.

    Drugs. 2007;67(3):435-55. Review.PMID: 17335299 [PubMed - indexed for MEDLINE]Related articles

    14.

    Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.

    Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M.

    J Inherit Metab Dis. 2003;26(7):617-27.PMID: 14707510 [PubMed - indexed for MEDLINE]Related articles

    15.

    Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.

    Mignani R, Feriozzi S, Pisani A, Cioni A, Comotti C, Cossu M, Foschi A, Giudicissi A, Gotti E, Lozupone VA, Marchini F, Martinelli F, Bianco F, Panichi V, Procaccini DA, Ragazzoni E, Serra A, Soliani F, Spinelli L, Torti G, Veroux M, Cianciaruso B, Cagnoli L.

    Nephrol Dial Transplant. 2008 May;23(5):1628-35. Epub 2007 Dec 5.PMID: 18057066 [PubMed - indexed for MEDLINE]Related articles

    16.

    Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.

    Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N.

    Nephrol Dial Transplant. 2007 Jul;22(7):1920-5. Epub 2007 Mar 29.PMID: 17395657 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Enzyme replacement therapy of Fabry disease.

    Clarke JT, Iwanochko RM.

    Mol Neurobiol. 2005 Aug;32(1):43-50. Review.PMID: 16077182 [PubMed - indexed for MEDLINE]Related articles

    18.

    [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy]

    Rivera Gallego A, López Rodríguez M, Barbado Hernández FJ, Barba Romero MA, García de Lorenzo Y Mateos A, Pintos Morelle G; Grupo Español de Estudio de Fabry Outcome Survey.

    Med Clin (Barc). 2006 Oct 7;127(13):481-4. Spanish. PMID: 17043001 [PubMed - indexed for MEDLINE]Related articles

    19.

    Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.

    Mignani R, Panichi V, Giudicissi A, Taccola D, Boscaro F, Feletti C, Moneti G, Cagnoli L.

    Kidney Int. 2004 Apr;65(4):1381-5.PMID: 15086478 [PubMed - indexed for MEDLINE]Related articles

    20.

    Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

    Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO.

    JAMA. 2001 Jun 6;285(21):2743-9.PMID: 11386930 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Find related data